Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting

被引：0
|
作者：
Bu, Qiling [1 ]
Zhu, Hong-Hu [1 ,2 ]
Chen, Wenming [1 ]
机构：
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Hematol, 8 Gongtinanlu, Beijing 100020, Peoples R China
[2] Chinese Inst Med Res, Beijing 100005, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2025年 / 18卷 / 01期
关键词：
Immunoglobulin light chain amyloidosis; Targeted therapies; Clinical trials;
D O I：
10.1186/s13045-025-01681-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Use of novel therapies in the treatment of light chain amyloidosis
    Varga, Cindy
    Titus, Stephanie E.
    Toskic, Denis
    Comenzo, Raymond L.
    BLOOD REVIEWS, 2019, 37
  • [32] Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
    Ji-nuo Wang
    Tianning Gu
    Yongxian Hu
    He Huang
    Experimental Hematology & Oncology, 11
  • [33] Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
    Jing-Zhou Hou
    Jing Christine Ye
    Jeffrey J. Pu
    Hongtao Liu
    Wei Ding
    Hong Zheng
    Delong Liu
    Journal of Hematology & Oncology, 14
  • [34] Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
    Wang, Ji-Nuo
    Gu, Tianning
    Hu, Yongxian
    Huang, He
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [35] Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
    Hou, Jing-Zhou
    Ye, Jing Christine
    Pu, Jeffrey J.
    Liu, Hongtao
    Ding, Wei
    Zheng, Hong
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [36] Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
    Chen, Yiyin
    Xu, Yang
    Wu, Depei
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [37] CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
    Huang, Qiusha
    Zhang, Xiao-hui
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [38] Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
    Yiyin Chen
    Yang Xu
    Depei Wu
    Experimental Hematology & Oncology, 12
  • [39] CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
    Qiusha Huang
    Xiao-hui Zhang
    Delong Liu
    Journal of Hematology & Oncology, 16
  • [40] Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside
    Basset, Marco
    Nuvolone, Mario
    Palladini, Giovanni
    Merlini, Giampaolo
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 1003 - 1015
12345